Abstracts Archive - Page 2539 of 2607 - ACR Meeting Abstracts

Abstract Number: 957 • 2012 ACR/ARHP Annual Meeting
Key Psychological Processes Associated with the Fibromyalgia Phenotype Exist On a Continuous Spectrum with Asymptomatic People
Katrina Malin¹ and Geoffrey O. Littlejohn², ¹Medicine, Monash University, Clayton, Australia, ²Rheumatology, Monash Medical Centre and Monash University, Clayton, VIC, Australia
Background/Purpose: The core features of the fibromyalgia phenotype, the widespread pain and widespread tenderness, represent one extreme of a continuous spectrum with asymptomatic people at…
Abstract Number: 958 • 2012 ACR/ARHP Annual Meeting
Prevelance of Spondyloarthropathy in Fibromyalgia Patients
A.Eftal Yucel¹, Derya Kaskari¹ and Muhtesem Agýldere², ¹Int Medicine Rheumatology, Baskent University, Ankara, Turkey, ²Radiology, Baskent University, Ankara, Turkey
Background/Purpose: Most of the tender points typical for fibromyalgia syndrome (FMS) are also entesis points. Besides, FMS and spondyloartropathy (SpA) can co-exist. Both disease groups…
Abstract Number: 960 • 2012 ACR/ARHP Annual Meeting
Cyclobenzaprine (CBP) and Its Major Metabolite Norcyclobenzaprine (nCBP) Are Potent Antagonists of Human Serotonin Receptor 2a (5HT2a), Histamine Receptor H-1 and á-Adrenergic Receptors: Mechanistic and Safety Implications for Treating Fibromyalgia Syndrome by Improving Sleep Quality
Bruce Daugherty, Leland Gershell and Seth Lederman, Research and Development, Tonix Pharmaceuticals, Inc., New York, NY
Background/Purpose: Bedtime cyclobenzaprine (CBP) improves fibromyalgia symptoms (pain, fatigue, tenderness, and mood) and improves sleep quality (decreases Cyclic Alternating Pattern Type A2 + A3) (1).…
Abstract Number: 961 • 2012 ACR/ARHP Annual Meeting
Cerebral Grey and White Matter Changes in Fibromyalgia Depend On Patients’ Age
Marta Ceko¹, Mary-Ann Fitzcharles², M. Catherine Bushnell¹ and Petra Schweinhardt¹, ¹McGill University, Montreal, QC, Canada, ²Rheumatology and Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Fibromyalgia (FM) patients show accelerated age-related decrease of grey matter (GM). Similarly, brain imaging studies in other chronic pain populations suggest interaction between age…
Abstract Number: 962 • 2012 ACR/ARHP Annual Meeting
Pain, Sleep Disturbance, and Depression Mediate the Association Between Body Mass Index and Fatigue in Fibromyalgia
Mary O. Whipple¹, Loren L. Toussaint², Daniel J. Clauw³, David A. Williams⁴, Terry H. Oh⁵, Jeffrey M. Thompson⁵, Connie A. Luedtke⁶ and Ann Vincent⁷, ¹Fibromyalgia and Chronic Fatigue Clinic, Mayo Clinic, Rochester, MN, ²Psychology, Luther College, Decorah, IA, ³Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI, ⁴Chronic Pain & Fatigue Rsch Ctr, Univ of MI Hlth System-Lobby M, Ann Arbor, MI, ⁵Physical Medicine & Rehabilitation, Mayo Clinic, Rochester, MN, ⁶Department of Nursing, Mayo Clinic, Rochester, MN, ⁷General Internal Medicine, Mayo Clinic, Rochester, MN
Background/Purpose: Previous research and clinical observation suggest that patients with chronic disease who are obese report significant fatigue. Our objective was to explore similar relationships in…
Abstract Number: 963 • 2012 ACR/ARHP Annual Meeting
Efficacy of Long-Term Milnacipran Treatment in Patients Meeting Different Thresholds of Clinically Relevant Pain Relief: Subgroup Analysis of a Double-Blind, Placebo-Controlled Discontinuation Study
Daniel J. Clauw¹, Philip J. Mease², Robert H. Palmer³, Joel M. Trugman⁴ and Yimin Ma⁴, ¹Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Forest Research Institute, Inc., Jersey City, NJ, ⁴Forest Research Institute, Jersey City, NJ
Background/Purpose: Patients with fibromyalgia (FM) who received up to 3.25 years of milnacipran (MLN) in a flexible-dose (≤200 mg/d) open-label (OL) study were eligible to…
Abstract Number: 964 • 2012 ACR/ARHP Annual Meeting
High-Energy Extracorporeal Shock Wave Therapy Is Effective for Treating Chronic Calcific Tendonitis of the Shoulder: A Meta-Analysis
Nina E. Flavin¹, Raveendhara R. Bannuru¹, William F. Harvey¹ and Timothy E. McAlindon², ¹Rheumatology, Tufts Medical Center, Boston, MA, ²Division of Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose: Calcific tendonitis (CT) and noncalcific tendonitis (NCT) of the shoulder is a common cause of shoulder pain and can be unresponsive to conventional therapies.…
Abstract Number: 965 • 2012 ACR/ARHP Annual Meeting
Increased Number of Painful Body Sites Is Associated with Worse Pain and Disability-Associated Outcomes Among Returning Operations Enduring Freedom/Operation Iraqi Freedom Service Members
Dennis C. Ang¹, Jingwei Wu², Samantha Outcalt³, Zhangsheng Yu⁴ and Matthew Bair³, ¹Indiana University, Indianapolis, IN, ²Biostatistics, Indiana University School of Medicine, ³VA Center on Implementing Evidence-Based Practice, Indiana University School of Medicine, ⁴Department of Biostatistics, Indiana University School of Medicine
Background/Purpose: Chronic pain is a critical health problem among Operations Enduring Freedom/Operation Iraqi Freedom service members. The deleterious impact of chronic pain on quality of…
Abstract Number: 966 • 2012 ACR/ARHP Annual Meeting
A Systematic Review of Evidence for the Effectiveness of Practitioner-Based Complementary and Alternative Therapies in the Management of Fibromyalgia
Gareth T. Jones¹, Priya Paudyal², Gary J. Macfarlane¹ and the Arthritis Research UK Working Group on Complementary and³, ¹Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ²Peninsula College of Medicine and Dentistry, University of Plymouth, Plymouth, United Kingdom, ³Aberdeen
Background/Purpose: Approximately one-quarter of the UK population uses complementary or alternative treatments (CAM) each year, and this is higher among persons with pain, or musculoskeletal…
Abstract Number: 967 • 2012 ACR/ARHP Annual Meeting
Haplotypes of GTP Cyclophydrolase Gene Polymorphisms Are Protective in the Susceptibility of Fibromyalgia Syndrome
Hwajeong Lee¹, Shin-Seok Lee², Seong-Kyu Kim³, Jung-Yoon Choe⁴, Seong-Ho Kim KIM⁵, Seong-Su Nah⁶, Ji Hyun Lee⁷, Seung-Jae Hong⁸, Hyun-Sook Kim⁹, Hye-Soon Lee¹⁰, Hyun Ah Kim¹¹ and Chung-Il Joung¹², ¹Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, South Korea, ²Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ³Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁵Department of Internal Medicine,, Inje University Haeundae Paik Hospital, Busan, South Korea, ⁶Department of Internal Medicine, Soonchunhyang University, College of Medicine, Cheonan, South Korea, ⁷Division of Rheumatology, Department of Internal Medicine, Maryknoll Medical Center, Busan, South Korea, ⁸Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, ⁹Internal Medicine, Chosun University Hospital, Gwangju, South Korea, ¹⁰Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ¹¹Division of Rheumatology, Department of Internal Medicine, Hallym university, Kyunggi, South Korea, ¹²Department of Internal Medicine, Konyang university hospital, Daejeon, South Korea
Background/Purpose: Guanosine triphosphate cyclohydrolase 1 (GCH1) is the rate-limiting enzyme in the synthesis of tetrahydrobiopterin, which is an essential co-factor in nitric oxide (NO) production.…
Abstract Number: 968 • 2012 ACR/ARHP Annual Meeting
Sympathetic Nervous System Dysfunction in Fibromyalgia and in Overlapping Central Sensitivity Syndromes. A Systematic Review of Controlled Studies
Laura Aline Martinez¹, Tania Mora¹, Angelica Vargas¹, Mario Fuentes¹ and Manuel Martinez-Lavin², ¹Rheumatology, National Institute of Cardiology, Mexico City, Mexico, ²Chief Rheumatology, National Institute of Cardiology, Mexico City, Mexico
Background/Purpose: Fibromyalgia often coexists and overlaps with other common painful syndromes such as chronic fatigue, irritable bowel and interstitial cystitis. Yunus proposed the label “central…
Abstract Number: 969 • 2012 ACR/ARHP Annual Meeting
Presence of Small Fiber Neuropathy in a Cohort of Patients with Fibromyalgia
Todd Levine¹, Victoria Lawson², Aidan Levine¹, Kevin V. Hackshaw³ and David Saperstein¹, ¹Phoenix Neurological Associates, Phoenix, AZ, ²Neurology, Ohio State University, Columbus, OH, ³Immunology/Rheumatology, The Ohio State University, Columbus, OH
Background/Purpose: The pain associated with fibromyalgia is classically described as deep, muscular, aching and flu-like; however, a significant percentage of patients with fibromyalgia also describe…
Abstract Number: 970 • 2012 ACR/ARHP Annual Meeting
Genetic Interactions Between SNP Variants in C3 Receptor Subunits in Patients with SLE
Jeffrey C. Edberg¹, Christine W. Duarte², Amit Patki², Elizabeth E. Brown MPH³, Kenneth M. Kaufman⁴, Jennifer A. Kelly⁵, Mary E. Comeau⁶, Marta E. Alarcon-Riquelme on behalf of BIOLUPUS and GENLES⁷, Sang-Cheol Bae⁸, Lindsey A. Criswell⁹, Barry I. Freedman¹⁰, Patrick M. Gaffney¹¹, Gary S. Gilkeson¹², Chaim O. Jacob¹³, Judith A. James⁵, Diane L. Kamen¹⁴, Kathy Moser Sivils⁵, Timothy B. Niewold¹⁵, Robert H. Scofield¹⁶, Betty P. Tsao¹⁷, Timothy J. Vyse¹⁸, John B. Harley¹⁹, Carl D. Langefeld²⁰, Hemant Tiwari² and Robert P. Kimberly²¹, ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴1Center for Autoimmune Genomics and Etiology and Rheumatology Division, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Wake Forest University Health Sciences, Winston-Salem, NC, ⁷Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK, ⁸Hanyang University Hospital for Rheumatic Disease, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, ⁹Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ¹⁰Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, ¹¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ¹³Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ¹⁴Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, ¹⁵Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ¹⁶Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ¹⁷Medicine/Rheumatology, UCLA School of Medicine, Los Angeles, CA, ¹⁸Medical & Molecular Genetics, King's College London, London, United Kingdom, ¹⁹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ²⁰Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ²¹Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Genome-wide and candidate gene studies have supported a role for genes involved in immune complex processing as being important contributors to development of SLE. …
Abstract Number: 971 • 2012 ACR/ARHP Annual Meeting
Association of adam33 Polymorphisms with Systemic Lupus Erythematosus
Seung Cheol Shim¹, Mi Kyoung Lim¹, Donghyuk Sheen² and Hyo Park¹, ¹Medicine, Eulji University Hospital, Daejeon, South Korea, ²Rheumatology, Eulji University Hospital, Daejeon, South Korea
Background/Purpose: A Disintegrin and Metalloprotease 33 (ADAM33) is a member of a family of genes that encode membrane-anchored proteins with a disintegrin and a metalloprotease…
Abstract Number: 972 • 2012 ACR/ARHP Annual Meeting
Associations of Genetic Polymorphisms of Microrna-146a and Its Target Interleukin-1-Receptor-Associated Kinase 1 with Ankylosing Spondylitis
Chun-Huang Huang¹, Jia-Yan Zhan², Kai-Jieh Yeo³, James C. Wei⁴, Chih-Shien Chuang² and Ruey-Hong Wong², ¹Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, ²Department of Public Health, Chung Shan Medical University, Taichung, Taiwan, ³Division of Allergy, Immunology and Rheumatology, Chung Shan Med Univ Hospital, Taichung, Taiwan, ⁴Allergy/Immunology/Rheumatolog, Chung Shan Med Univ Hospital, Taichung, Taiwan
Background/Purpose: Tumor necrosis factor-α (TNF-α) and interleukin-1 (IL-1) were important mediators of inflammation response in the development of ankylosing spondylitis (AS). Especially, microRNA (miR)-146a targets…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].